Cover Image
市場調查報告書

惡性神經膠質瘤 - 開發平台分析

Malignant Glioma - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 271834
出版日期 內容資訊 英文 116 Pages
訂單完成後即時交付
價格
Back to Top
惡性神經膠質瘤 - 開發平台分析 Malignant Glioma - Pipeline Review, H2 2015
出版日期: 2015年07月31日 內容資訊: 英文 116 Pages
簡介

惡性神經膠質瘤是最常見的腦瘤,常見的症狀有痙攣和記憶力衰退,四肢無力感,無法控制肌肉,視覺症狀,語言障礙,認知功能低落,人格的變化等。治療方法有外科手術,化療,放射治療等。

本報告提供惡性神經膠質瘤的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃的相關資訊,以及最新的新聞和發表。

簡介

  • 調查範圍
  • 惡性神經膠質瘤 概要

治療藥的開發

  • 開發中產品;Malignant Glioma;概要
  • 開發中產品;Malignant Glioma;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥開發企業

  • Sanofi
  • ZIOPHARM Oncology, Inc.
  • Cytomedix, Inc.
  • Stemline Therapeutics, Inc.
  • EirGen Pharma Ltd.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • Eir-060
  • WT-1 Peptide Vaccine
  • Cell Therapy for Oncology
  • Dendritic Cell Vaccine
  • Carboxyamidotriazole Orotate
  • SL-701
  • SAR-245409
  • WT1 Peptide Vaccine
  • Cell Therapy for Malignant Gliomas
  • Vaccine Targeting Survivin for Malignant Glioma
  • Ad-RTS-IL-12
  • ALD-451
  • First Generation Attenuated Strain Of Reovirus

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC6872IDB

Summary

Global Markets Direct's, 'Malignant Glioma - Pipeline Review, H2 2015', provides an overview of the Malignant Glioma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Malignant Glioma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Malignant Glioma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Malignant Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Malignant Glioma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Malignant Glioma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Malignant Glioma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Malignant Glioma Overview
  • Therapeutics Development
    • Pipeline Products for Malignant Glioma - Overview
    • Pipeline Products for Malignant Glioma - Comparative Analysis
  • Malignant Glioma - Therapeutics under Development by Companies
  • Malignant Glioma - Therapeutics under Investigation by Universities/Institutes
  • Malignant Glioma - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Malignant Glioma - Products under Development by Companies
  • Malignant Glioma - Products under Investigation by Universities/Institutes
  • Malignant Glioma - Companies Involved in Therapeutics Development
    • Advantagene, Inc.
    • Amgen Inc.
    • AstraZeneca Plc
    • BBB Therapeutics B.V.
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • Genmab A/S
    • Lipopharma Therapeutics SL
    • MediGene AG
    • Nuo Therapeutics, Inc.
    • Pfizer Inc.
    • Stemline Therapeutics, Inc.
    • Tiziana Life Sciences Plc
    • Vicus Therapeutics, LLC
    • ZIOPHARM Oncology, Inc.
  • Malignant Glioma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (etodolac + propranolol hydrochloride) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • 2B3-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Ad-RTS-IL-12 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALD-451 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Carboxyamidotriazole Orotate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell therapy for Malignant Glioma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy for Refractory Gliomas - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy to Target EGFR for Malignant Glioma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy to Target IL-13 for Malignant Glioma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Dendritic Cell Therapy for Malignant Gliomas - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Dendritic Cell Therapy for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Dendritic Cell Therapy for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Dendritic Cell Therapy for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Dendritic Cell Therapy for Recurrent Malignant Glioma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • disufenton sodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DNX-2401 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • G-207 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • galunisertib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GliAtak - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IDD-004 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • irofulven - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LD-224 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • marizomib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • milciclib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Minerval - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugated to Antagonize EGFR for Brain Tumor and Glioblastoma Multiforme - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rilotumumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SL-701 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Brain Cancer and Malignant Glioma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • temsirolimus - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine to Target Wilm's Tumor 1 for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Malignant Glioma - Recent Pipeline Updates
  • Malignant Glioma - Dormant Projects
  • Malignant Glioma - Discontinued Products
  • Malignant Glioma - Product Development Milestones
    • Featured News & Press Releases
      • Jul 24, 2015: ZIOPHARM Announces Orphan Drug Designation for Ad-RTS-hIL-12 in the Treatment of Malignant Glioma
      • Apr 07, 2015: Key patent for Minerval in oncology granted in the United States by the USPTO
      • Oct 07, 2014: FDA Grants Orphan Drug Designation To DNAtrix's DNX-2401 For The Treatment Of Malignant Glioma
      • Feb 24, 2014: DNAtrix Awarded $10.8 Million Grant by the Cancer Prevention and Research Institute of Texas
      • Nov 19, 2012: Aeterna Zentaris Announces Positive Data From Phase I Trial Of Perifosine Combined With Temsirolimus In Malignant Glioma
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Malignant Glioma, H2 2015
  • Number of Products under Development for Malignant Glioma - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Malignant Glioma - Pipeline by Advantagene, Inc., H2 2015
  • Malignant Glioma - Pipeline by Amgen Inc., H2 2015
  • Malignant Glioma - Pipeline by AstraZeneca Plc, H2 2015
  • Malignant Glioma - Pipeline by BBB Therapeutics B.V., H2 2015
  • Malignant Glioma - Pipeline by Eisai Co., Ltd., H2 2015
  • Malignant Glioma - Pipeline by Eli Lilly and Company, H2 2015
  • Malignant Glioma - Pipeline by Genmab A/S, H2 2015
  • Malignant Glioma - Pipeline by Lipopharma Therapeutics SL, H2 2015
  • Malignant Glioma - Pipeline by MediGene AG, H2 2015
  • Malignant Glioma - Pipeline by Nuo Therapeutics, Inc., H2 2015
  • Malignant Glioma - Pipeline by Pfizer Inc., H2 2015
  • Malignant Glioma - Pipeline by Stemline Therapeutics, Inc., H2 2015
  • Malignant Glioma - Pipeline by Tiziana Life Sciences Plc, H2 2015
  • Malignant Glioma - Pipeline by Vicus Therapeutics, LLC, H2 2015
  • Malignant Glioma - Pipeline by ZIOPHARM Oncology, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Malignant Glioma Therapeutics - Recent Pipeline Updates, H2 2015
  • Malignant Glioma - Dormant Projects, H2 2015
  • Malignant Glioma - Dormant Projects (Contd..1), H2 2015
  • Malignant Glioma - Dormant Projects (Contd..2), H2 2015
  • Malignant Glioma - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Malignant Glioma, H2 2015
  • Number of Products under Development for Malignant Glioma - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top